Solving the biggest problem in drug development.

Overview
DOPPL can grow, screen, and analyze thousands of samples of human tissue at once. It enables us to predict patient responses and identify new drug targets.

Human tissues
At the core of our MIRA platform is a robotic system that grows dozens of different types of organoids from human tissue like healthy intestine, lung, stomach and various cancer tissues, like ovarian, pancreatic and sarcomas.

Why now?
The FDA modernized the law in 2023 to replace animal testing by alternative methods like the DOPPL organoid platform.

Organoid meaning
Organoids are lab-grown three-dimensional miniature organ models, derived from patients' own cells providing an unlimited testing ground. They are a much better representation of how a human would respond to a drug compared to any animal or collection of immortalized 2D cells typically used in pharma today. DOPPL sources tissues under ethical principles of consent from living patients.

Contact
Jeroen van den Oever
jeroen@doppl.ch
+41 79 272 49 95
http://doppl.ch

COMPANY PRESENTATION

DOPPL SA, a Swiss biotech company founded in 2022 has developed a solution that dramatically improves the success rate for drugs to pass clinical trials. We are specialized in human organ and disease modeling for intestinal diseases and oncolog, offering an end-to-end prediction platform for preclinical drug discovery and development.

We grow complex human miniature organs that mimic patient function in the dish while ensuring reproducibility and consistency across screening campaigns through **large-scale robotic automation**. DOPPL also developed AI algorithms to predict patient responses from our lab grown human tissues. As the company grows more tissues, it generates more data to maximize the **accuracy of this prediction**.

DOPPL offers a range of services for pre-clinical development, such as target identification/validation, drug identification/validation as well as toxicity assessment services. With this offering, **we engage in royalty and milestone-based programs**. We aim at running 20 programs per year with our partners while building a large and diversified portfolio of **stakes in future therapeutics**.

Our market is protected by a **strong IP** portfolio that has established the company as the leader in the industry with no need to in license or partner with other market players. 100% of our work is performed on ethically sourced human tissues. **No animals** are used.

We partner with the **global leading pharmaceutical companies**, among them Roche, Novartis, Bayer, AstraZeneca as well as leaders in nutrition and AI such as Nestle and Owkin. We run partner-initiated programs with special focus on **AI-powered target and hit discovery** plugged to our biobank of **real-world human mini-tissues and data** to generate **wholly owned drug assets**.

MARKET OVERVIEW

95% of compounds that enter the drug discovery process fail. Pharmaceutical companies spend **USD 71.4 Bn yearly**[1] in drug discovery chasing huge markets. With an ever-aging population more complex diseases arise, that cannot be solved by traditional block buster drugs. Complex diseases typically require more precise care and treatments.

Our target market is the organoid market and is expected to grow to $2 Bn by 2025, growing at a **CAGR of 17.5%**[2]**.** Two drivers are responsible for this **strong market growth**. The pharmaceutical industry faces a patent cliff as 50% of top selling drugs patents will expire by 2030[3]. The FDA modernization act[4] stipulates that animal testing can now be replaced by alternative methods.

Pharmaceutical and biotech companies are stuck with too high costs for too little output. Driven by a translational gap between pre-clinical and clinical data, drug development needs **alternatives to mitigate risks** when developing their assets.





Use case of DOPPL's MIRA platform for designing and re-exploring therapeutic potentials of drug combinations for childhood sarcoma patients in collaboration with the Centre Léon Bérard in Lyon France.[5]

Management Team / Relevant Experience

- The management team is composed experienced **serial entrepreneurs working together since 2017**.
- Jeroen Van den Oever (CPA, M.Sc., MBA) has a demonstrated history of working in the investment and finance industry including large global corporates as KPMG and the IOC with **successful exits** in Banking and Finance Consulting.
- Dr. Nathalie Brandenberg (Ph.D in Bioengineering and Biotechnology, eMBA UNIL) and Dr. Sylke Hoehnel-Ka (Ph.D. in Bioengineering and Biotechnology, INSEAD) are **pioneers** of the organoid field having done their PhDs in the laboratory of Prof. Matthias Lutolf at EPFL, now Director of the Institute of Human Biology at F. Hoffmann-La Roche in Basel, who is a shareholder himself of DOPPL.
- Together, the team brings 20+ years of experience with a track record in building successful companies in the organoid field and finance and close ties to clinics and Basel-based pharmaceutical stakeholders.
- The core team is surrounded by a strong operations team composed of seasoned managers in their respective fields of expertise. They are responsible of delivering on target and executing on the strategical developments of the company.
- Doppl is supported by a **strong network of key opinion leaders** including
  - Prof. Matthias Lutolf, Scientific Director of the Institute of Human Biology at Roche
  - Dr. Joseph Lehár, former Director at Novartis, Scientific Advisory Board Owkin)
  - Prof. Martin Vetterli, President of EPFL
  - Prof. William-F. Pralong, Former co-president of the Cantonal Ethical Comission CER-VD)
  - Prof. Gerhard Rogler, MD and Director Clinic for Gastroenterology and Hepatology University Hospital Zurich (USZ)
  - Prof. Krisztian Homicsko, MD at University Hospital Lausanne (CHUV) and President of Tumor Board at CHUV.

Investment

- For 2024 the company expects revenue of approx. **MCHF 2.2** through further expansion of services. The EBITDA break-even is expected to be in 2025. The company offers an entry to invest in a strong growth market that benefits from a **change of regulations** driven by the FDA.
- With established IP, existing client portfolio, and operational technology the investment offers **limited downside risk** with **exceptional upsides** through partnerships with drug developers and healthcare AI companies at a market inflection point.
- Current investors and members of the board of directors include well-known investors and players in the field. Our team has been together for several years and is among the pioneers in the field with **established credibility** driving sales and adoption.
- DOPPL growth and development has been financed by MCHF 2.85 in non-dilutive grants and MCHF 3.4 in equity and debt.
- **Series A**: Growth equity financing round of up to **MCHF 18**. We will use the funds for in-house development programs, business development and expand the robotic platform in strategic geographies. **Envisaged closing: Q2 2024.**



Sources:
[1] Global Personalized Medicine Market – Technologies and Applications, ID: 4655540, October 2018
[2] Human Organoid Market, ID: BT 6218, December 2020
[3] Fierce Pharma, The top 15 blockbuster patent expirations coming this decade, June 2021
[4] FDA Modernization Act 2.0 decision, https://www.congress.gov/bill/117th-congress/senate-bill/5002
[5] Scientific peer-reviewed publication: https://doi.org/10.1016/j.xcrm.2023.101339